Fund Holdings — Frazier Life Sciences Management, L.P.

Total Portfolio Value:
$4.03B
Total Bought:
$633.90M
Total Sold:
$511.20M
Net Transaction:
+$122.70M
Notable People:
James Newman Topper, Patrick James Heron, Daniel Estes, James Brush, Albert (Nmn) Cha, Frazier Life Sciences Management,
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Mirum Pharmaceuticals, Inc.(MIRM)7,679,6847,679,6840$899.06M$656.46M16.29%-$242.60M
Newamsterdam Pharma Company
ORDINARY SHARES
18,088,90218,988,902+900,000$613.03M$461.81M11.46%-$151.22M
Erasca, Inc.(ERAS)24,975,18829,475,188+4,500,000$457.55M$432.11M10.72%-$25.44M
MBX Biosciences, Inc.(MBX)6,652,0136,652,0130$367.19M$389.94M9.67%+$22.75M
Arcutis Biotherapeutics, Inc.(ARQT)9,874,5119,874,5110$258.91M$260.98M6.48%+$2.07M
Maze Therapeutics, Inc.(MAZE)5,032,9155,282,915+250,000$150.18M$143.59M3.56%-$6.59M
Trevi Therapeutics, Inc.(TRVI)9,939,4479,539,147-400,300$185.37M$136.60M3.39%-$48.77M
Krystal Biotech, Inc.(KRYS)481,307391,319-89,988$178.89M$130.14M3.23%-$48.75M
Palvella Therapeutics, Inc.(PVLA)882,400882,4000$134.85M$121.71M3.02%-$13.14M
Attovia Therapeutics Inc07,046,271+7,046,271$0$120.77M3.00%+$120.77M
Braveheart Bio Inc05,267,321+5,267,321$0$106.40M2.64%+$106.40M
Phathom Pharmaceuticals Inc12,466,48912,466,4890$135.26M$91.01M2.26%-$44.26M
Parabilis Medicines Inc1,920,8052,330,750+409,945$52.57M$75.26M1.87%+$22.69M
Dyne Therapeutics, Inc.(DYN)3,153,0823,853,082+700,000$70.03M$62.07M1.54%-$7.96M
Achieve Life Science Inc7,614,8367,614,8360$49.72M$61.60M1.53%+$11.88M
MannKind Corporation(MNKD)6,600,00015,755,491+9,155,491$28.12M$61.45M1.52%+$33.33M
Disc Medicine, Inc.(IRON)1,354,852934,852-420,000$99.09M$61.20M1.52%-$37.90M
Tarsus Pharmaceuticals, Inc.(TARS)728,644720,338-8,306$45.86M$56.63M1.40%+$10.76M
Vor Biopharma Inc.(VOR)2,543,9392,743,939+200,000$46.83M$52.35M1.30%+$5.52M
Ascendis Pharma A/S(ASND)0225,155+225,155$0$51.30M1.27%+$51.30M
Zai Lab LimitedADR(ZLAB)1,902,3201,902,3200$36.14M$50.11M1.24%+$13.96M
Aclaris Therapeutics Inc4,925,3748,729,516+3,804,142$26.06M$45.92M1.14%+$19.86M
Aura Biosciences Inc7,100,0007,100,0000$50.41M$44.59M1.11%-$5.82M
Allogene Therapeutics Inc22,446,66822,446,6680$46.69M$35.91M0.89%-$10.77M
BioCryst Pharmaceuticals, Inc.(BCRX)4,009,2404,009,2400$40.09M$33.40M0.83%-$6.70M
Celldex Therapeutics, Inc.(CLDX)0900,080+900,080$0$29.17M0.72%+$29.17M
Acadia Pharmaceuticals Inc1,438,1981,438,1980$36.39M$28.98M0.72%-$7.41M
Shattuck Labs Inc3,750,0003,750,0000$26.02M$25.57M0.63%-$450.0K
Immunocore Holdings plcADS(IMCR)484,782829,752+344,970$15.39M$25.13M0.62%+$9.74M
Design Therapeutics Inc1,809,8541,809,8540$26.19M$22.75M0.56%-$3.44M
Evolus Inc2,630,6652,630,6650$18.26M$21.05M0.52%+$2.79M
Sarepta Therapeutics, Inc.(SRPT)01,069,959+1,069,959$0$19.49M0.48%+$19.49M
Relay Therapeutics, Inc.(RLAY)1,015,6931,015,6930$19.00M$18.33M0.45%-$670.4K
Lexeo Therapeutics Inc4,824,7254,824,7250$22.46M$16.31M0.40%-$6.15M
Valneva SeADS2,291,6662,291,6660$11.99M$14.17M0.35%+$2.19M
Kailera Therapeutics Inc1,100,0001,200,000+100,000$24.23M$13.70M0.34%-$10.53M
Monte Rosa Therapeutics Inc1,000,0001,000,0000$24.20M$11.93M0.30%-$12.27M
Oric Pharmaceuticals Inc0751,672+751,672$0$10.13M0.25%+$10.13M
Autolus Therapeutics LtdADS4,447,9104,447,9100$7.12M$8.63M0.21%+$1.51M
Newamsterdam Pharma CompanyW EXP 99 99 999
*W EXP 99/99/999
500,333500,3330$10.69M$6.33M0.16%-$4.36M
Savara Inc.(SVRA)9,720,8521,113,752-8,607,100$59.88M$5.75M0.14%-$54.13M
Xilio Therapeutics Inc422,505422,5050$4.05M$3.82M0.09%-$223.9K
Tcgx Acquisition CorpCL A0300,000+300,000$0$3.75M0.09%+$3.75M
Ibio Inc1,953,4671,953,4670$3.42M$2.31M0.06%-$1.11M
Alkermes plcSHS(ALKS)700,6470-700,647$36.71M$0—-$36.71M
Ascendis Pharma A/SADR(ASND)225,1550-225,155$60.05M$0—-$60.05M
BridgeBio Pharma, Inc.(BBIO)1,548,1390-1,548,139$115.31M$0—-$115.31M
Cytokinetics, Incorporated(CYTK)1,159,8790-1,159,879$98.81M$0—-$98.81M
Page 1 of 1
Frazier Life Sciences Management, L.P. — 13F Holdings — Q3 2026 | TickerTrail